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(NOACs) should discontinue these drugs 24 to 
36 hours before surgery. It is not recommend‑
ed to use bridging anticoagulant therapy in pa‑
tients on NOACs.
Which anticoagulants should be used for patients with 
atrial fibrillation and cancer? In the management 
of patients with atrial fibrillation (AF) and can‑
cer, VKAs or NOACs can be used for stroke pre‑
vention. However, the effectiveness and safety of 
treatment with NOACs in this specific group of 
patients are poorly documented because these pa‑
tients have not been included in large randomized 
clinical trials on the use of NOACs in AF. How‑
ever, clinical practice shows that NOACs are well 
tolerated by most cancer patients in good general 
condition, receiving outpatient cancer treatment, 
and with low ‑to ‑moderate bleeding risk, and not 
taking antifungal drugs or cyclosporine. In every‑
day practice, however, LMWH are mostly used in 
patients with venous thromboembolism (VTE), 
and not with AF, except when such management 
is planned only for a short time and because of 
invasive procedures, nausea, vomiting, or diar‑
rhea, and other complications of an underlying 
disease. The effectiveness of LMWH (particular‑
ly at prophylactic or moderate doses) in AF, es‑
pecially in high ‑risk patients is unknown; how‑
ever, in high ‑risk cancer inpatients with elevat‑
ed risk of bleeding LMWH should be considered. 
Anticoagulation strategy should be individualized 
in cancer patients especially if both bleeding and 
thrombosis risks are high.
Is anticoagulant therapy beneficial for a patient with 
a survival probability of 0.5 to 1 year, who is on palli‑
ative treatment because of heart failure with AF? Is it 
reasonable to maintain this patient on such a therapy? 
There has been no clinical trials regarding pa‑
tients with such a bad prognosis requiring an‑
ticoagulation. The decision should be based on 
the classic risk scores, such as the CHA2DS2‑
‑VASc score to assess the thromboembolic risk 
How do we prepare a patient on oral anticoagulation 
with vitamin K antagonists (VKAs) for cataract sur‑
gery? Patients treated with VKAs can undergo 
surgery when the value of an international nor‑
malized ratio (INR) is 2 or lower on the day of 
surgery. Cataract surgery is associated with low 
risk of bleeding complications (similarly to most 
dental procedures). The 2014 European Society of 
Cardiology (ESC) guidelines on preparing patients 
for noncardiac surgery and the 2008 guidelines of 
the American College of Chest Physicians clearly 
indicate that the cataract surgery, and more spe‑
cifically, preprocedural anesthesia, is not associat‑
ed with an increased risk of permanent vision im‑
pairment caused by hematoma. Prior to cataract 
surgery, bridging therapy with a low ‑molecular‑
‑weight heparin (LMWH) should not be used as 
a routine procedure because it is associated with 
a 2‑ to 3 ‑fold higher risk of bleeding without dif‑
ference in the risk of thromboembolism estimat‑
ed at lower than 1%. Moreover, the withdrawal of 
VKAs for at least 5 to 8 days and subsequent dose 
titration to return to therapeutic INRs that takes 
even up to a few days after surgery disturb the sta‑
bility of long ‑term anticoagulation and may also 
impose a greater risk on thromboembolic compli‑
cations in next weeks, especially among high ‑risk 
patients such as those with an implanted pros‑
thetic mitral valve and numerous comorbidities. 
Therefore, a patient before cataract surgery should 
not be treated in the same way as before an open 
abdominal surgery or neurosurgery. Nowadays, 
more and more cataract centers perform surgery 
in patients with INR values of about 2 and safely 
manage their patients without switching them to 
LMWH. The decision of whether to continue an‑
ticoagulation in the preoperative period is at the 
discretion of the performing surgeon supported 
by an internist, but VKAs should not be routine‑
ly withdrawn because of cataract surgery because 
this is not recommended by the current guidelines.
It is worth mentioning that patients taking 
non ‑vitamin K antagonist oral anticoagulants 
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Which anticoagulants, novel or old, are safer for pa‑
tients with gastrointestinal bleeding? If bleed‑
ing was major and its cause was unknown (eg, 
not during treatment with VKA or nonsteroi‑
dal anti ‑inflammatory drugs [NSAIDs], especial‑
ly cyclooxygenase ‑1 inhibitors), a NOAC, often 
at a reduced dose, should be initiated. The 2016 
ESC guidelines recommend reduced doses of NO‑
ACs in AF patients at high risk of gastrointesti‑
nal bleeding. Based on large clinical studies in 
patients with AF, experts recommend dabiga‑
tran at a dose of 2 × 110 mg/d or apixaban at a 
dose of 2 × 5 mg/d or 2 × 2.5 mg/d, or rivarox‑
aban 15 mg/d as the options to be considered. 
Apixaban and lower doses of dabigatran admin‑
istered to AF patients do not increase the risk of 
gastrointestinal bleeding compared with warfa‑
rin. In patients with persistent bleeding, espe‑
cially those older than 70 years (eg, with diver‑
ticulosis), the safest option in my opinion would 
be apixaban at a dose of 2 × 2.5 mg/d. Even if 
bleeding occurs during the use of apixaban, then 
the patient will rather not be able to take anti‑
coagulants. Patients with previous gastrointes‑
tinal bleeding should avoid the use of NSAIDs 
(paracetamol can be given instead as an anti‑
pyretic or analgesic agent), because in elderly pa‑
tients these drugs are the most common modi‑
fiable risk factor for bleeding. Proton pomp in‑
hibitors should be added to an anticoagulant to 
reduce upper gastrointestinal bleeding.
Is there an alternative for oral anticoagulants in pa‑
tients with prosthetic heart valves? Can we intro‑
duce a long ‑term treatment with LMWH, and if yes, 
at what doses? How to manage a patient with a pros‑
thetic heart valve, who takes acenocoumarol or war‑
farin and has an INR in the range of 8 to 11, despite 
previously stable values for many years? There 
is no alternative to the long ‑term use of VKAs 
in patients with prosthetic heart valves, either 
the currently implanted ones or those implant‑
ed in the past. INR may be optimized by diet, 
review of interfering drugs (including over ‑the‑
‑counter medications, such as herbal remedies), 
self ‑monitoring, etc. Two to three days on anti‑
biotics or with gastrointestinal symptoms lead‑
ing to diarrhea and reduced food intake could re‑
sult in an increase of INRs above 5. With unsta‑
ble INR values, it is most important to check for 
signs or symptoms of bleeding and measure INRs 
every 1 or 2 weeks, if feasible. Good clinical tol‑
erance of fluctuating INR values is a good prog‑
nostic factor in such patients. INR should then 
be measured more often, and when the require‑
ment for a VKA is low (≤2 mg/d of acenocouma‑
rol), low doses of oral vitamin K could be add‑
ed—then the requirement for the VKA increas‑
es and INR values stabilize. However, a special‑
ist should help manage such patients.
What are the most frequent adverse effects of aceno‑
coumarol and warfarin, except bleedings? Are severe 
skin reactions, vasculitis, and chronic and generalized 
in AF and the HAS ‑BLED score or others to as‑
sess the bleeding risk, but it has to be made on 
individual basis. Continued anticoagulant ther‑
apy may be considered in patients at high risk of 
thromboembolic events if kidney and liver func‑
tion is satisfactory and there is no anemia or re‑
current clinically relevant bleeding, because most 
patients would choose the perspective of living 
1 year without disabling stroke. It is suitable to 
administer a reduced dose of a NOAC in most 
such cases, namely, dabigatran (2 × 110 mg/d) 
or apixaban (2 × 2.5 mg/d), which are currently 
recommended as the safest options in patients 
with AF at high risk of bleeding.
How to treat patients in whom INR cannot be mea‑
sured because of older age, disability, inability to fol‑
low complex instructions, or refusal to use NOACs 
due to cost? Should LMWH or acetylsalicylic acid 
(ASA) be started? We should aim at minimizing 
the number of patients requiring long ‑term an‑
ticoagulation who are not treated according to 
the current guidelines in the European Union, be‑
cause other therapeutic options have minimal or 
uncertain effectiveness. In the United Kingdom 
and in the entire European Union, the use of ASA 
is not recommended for the prevention of stroke 
in AF since September 2016; the effectiveness 
of this agent is very limited with a 2‑fold higher 
risk of bleeding, particularly from the gastroin‑
testinal tract. Currently, it is unknown whether 
LMWH could decrease the risk of stroke because 
this issue has not been systematically studied 
in patients with AF so far. The use of LMWH is 
rather a short ‑term option (eg, in the perioper‑
ative period). The majority of patients will hard‑
ly accept the many years with everyday subcu‑
taneous injections. From my experience, LM‑
WHs at prophylactic or intermediate doses giv‑
en once daily (the half ‑time of this drug is about 
12 hours) do not protect against stroke, especial‑
ly if the CHA2DS2 ‑VASc score is high, and they 
are not well tolerated by patients (injections are 
administered for many weeks). Moreover, they 
are not even recommended by the guidelines as 
a therapeutic option in AF. The 2012 ESC guide‑
lines have recommended a combination therapy 
of ASA plus clopidogrel as an alternative to an‑
ticoagulants, but such an option is rarely used 
in practice and it disappeared in the 2016 ESC 
guidelines for AF. Undoubtedly, if a patient with 
AF refuses the treatment with any NOACs, a phy‑
sician should note that down in the patient’s 
medical records and consider administering ASA 
instead of oral anticoagulation as this option is 
supported by more reliable evidence than LM‑
WHs. The latter drugs could be used, if accept‑
able, in patients following VTE.
Finally, several measures to improve antico‑
agulation control in patients on VKAs should be 
undertaken, starting from dietary advice, review 
of potentially interfering comedications, etc.
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(including ASA) are contraindicated as they are 
associated with several episodes of upper gas‑
trointestinal bleeding, including in patients 
on NOACs.
Which analgesic or antipyretic can be given to a pa‑
tient on warfarin, acenocoumarol, dabigatran, or ri‑
varoxaban treatment? Paracetamol at a dose of 
up to 2 g/d is considered safe in patients with 
normal liver function. Also a combination ther‑
apy of paracetamol with codeine or tramadol can 
be used. Of note, higher doses of paracetamol 
administered for 3 to 5 days increase INRs and 
might destabilize anticoagulation with VKAs. 
Patients on warfarin, acenocoumarol, dabiga‑
tran, or rivaroxaban treatment should not be 
given NSAIDs, although most patients tolerate 
the short ‑term use of cyclooxygenase ‑1 inhibi‑
tors (especially patients with low bleeding risk). 
Therefore, the use of anticoagulants is not an ab‑
solute contraindication to the use of NSAIDs. 
However, such treatment should be adminis‑
tered with caution.
How does a short ‑term use of paracetamol, tramad‑
ol, or NSAIDs (administered for example during infec‑
tion or for acute pain) affect VKA treatment? These 
drugs have a minor effect on VKA treatment; only 
paracetamol >2 g/d for a few days increase INRs. 
By inhibiting platelet aggregation (via a mecha‑
nism similar to that of ASA), NSAIDs increase 
the bleeding tendency if a blood vessel is already 
damaged (eg, because of gastritis). In elderly peo‑
ple on anticoagulant treatment, it is always nec‑
essary to add a proton pump inhibitor, even if 
NSAIDs are prescribed only for a few days.
What is the pharmacologic management in case of 
bleeding in patients receiving rivaroxaban/dabiga‑
tran as prevention of thromboembolism during AF? 
After the episode of bleeding, should a NOAC be con‑
tinued at modified doses or should it be changed to 
a VKA along with a recommendation for more care‑
ful monitoring? After each bleeding episode in 
a patient using NOAC, the severity and cause of 
bleeding should be assessed. Bleeding tenden‑
cy observed prior to anticoagulation initiation 
should be excluded (bleedings, such as menstrual 
bleedings, are often worsened by anticoagulant 
therapy). Creatinine clearance should also be as‑
sessed and compared with the previous values, 
as well as complete blood cell count (particularly 
the platelet count). The use of other drugs (espe‑
cially NSAIDs) and bleeding episodes in the past 
should be recorded. Only serious bleeding should 
prompt a decision about the possible change of 
treatment, so bruises of 2 to 3 cm on the extrem‑
ities are in most cases the “price” for stroke pre‑
vention, and their presence should not be an in‑
dication for a change in therapy. Such a change is 
indicated when the thromboembolic risk is high 
(similarly as in the case of VKA therapy). What 
is necessary at all times is a diagnostic workup 
and treatment of the underlying organic cause 
pruritus common adverse effects of a long ‑term use of 
VKAs? When a drug change is indicated in such cases? 
Skin lesions, hair loss, and headaches can be 
the adverse effects of VKAs if other causes are 
excluded or unknown. In 2% of cases, elevated 
levels of liver enzymes could be observed, espe‑
cially in patients taking other hepatotoxic agents 
(eg, amiodarone) or having concomitant liver 
diseases. These symptoms are an indication for 
a drug switch if only possible. For example, there 
is no need for patients with nonvalvular AF to 
experience the side effects of VKAs if they can 
use NOACs instead, which are a preferred option 
for this indication.
Can dabigatran be continued after an episode of gas‑
trointestinal bleeding? I prescribed dabigatran at a 
dose of 150 mg bid to a patient with a high risk of VTE 
complications (based on the CHA2DS2 ‑VASc score) 
and an estimated glomerular filtration rate exceeding 
60 ml/min/1.73 m2. The patient had no previous gas‑
trointestinal symptoms. After a few months of dabi‑
gatran use, the patient suffered a massive upper gas‑
trointestinal hemorrhage, which required a transfu‑
sion of a few packed red blood cell units. Endoscopy 
revealed duodenal ulcer (no other symptoms except 
bleeding). The etiology of the ulcer could not be de‑
termined (whether it was the use of NSAIDs or He-
licobacter pylori infection), but the patient received 
treatment for Helicobacter pylori eradication in case 
it was present. Obviously, the risk of thromboembol‑
ic complications remained the same after the bleed‑
ing. Can we reinstitute dabigatran treatment on en‑
doscopic confirmation of ulcer healing? What anti‑
coagulant treatment should be used during the min‑
imum of 6 to 7 weeks of ulcer treatment? Beside 
the assessment of thromboembolic risk, also 
the bleeding risk should be assessed in patients 
with AF. Patients with low bleeding risk (like‑
ly in the case presented) will require a reduced 
dose of NOACs after an episode of bleeding. Ac‑
cording to indirect analyses of randomized tri‑
als and recent registries from the United States 
and Denmark, apixaban appears the safest oral 
anticoagulant in such cases. The risk of gastro‑
intestinal bleeding is significantly higher (by 
about 20%) in AF patients on dabigatran and 
rivaroxaban than in those on warfarin (accord‑
ing to the results of the RE ‑LY and ROCKET ‑AF 
trials), which is associated with the presence of 
an active form of a NOAC in the gastrointesti‑
nal tract. In this particular case, I would opt for 
apixaban 2 × 2.5 mg/d although a strong indica‑
tion to reduced doses is when the patient meets 
2 of the 3 criteria: body mass ≤60 kg, age ≥80 
years, and serum creatinine levels ≥133 µmol/l.
If the patient cannot afford apixaban, dabi‑
gatran or rivaroxaban can be introduced again 
usually after 4 weeks (and no later than 6 to 
8 weeks). As bridging therapy, LMWH is usu‑
ally used at intermediate doses (longer use of 
moderate doses or termination of the therapy 
may increase the risk of ischemic stroke) and 
always with a proton pump inhibitor. NSAIDs 
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discontinuing anticoagulation, then the with‑
drawal of ASA does not require prophylaxis with 
LMWH. It is necessary to ensure proper hydra‑
tion, use compression therapy (if these are com‑
plications of deep venous thrombosis), and en‑
sure that the patient is mobilized as soon as pos‑
sible. The use of LMWH should be limited to pa‑
tients treated with anticoagulants, who have 
a high or moderate risk of thromboembolism 
but low risk of bleeding (or lower than the risk 
of peripheral embolus or thrombosis, especial‑
ly on the prosthetic heart valve). Of note, up to 
1% of the patients treated with LMWH can de‑
velop heparin ‑induced thrombocytopenia, which 
is associated with a high risk of thromboembol‑
ic complications.
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(especially if it is located in the large intestine or 
urinary system). Bleeding from these sites can be 
a predictor of cancer, among other diseases, and 
it is wrong to assume that bleeding during anti‑
coagulant therapy originates only from a healthy 
organ and was caused only by the use of an anti‑
coagulant drug. Indications for a change in ther‑
apy after a serious bleeding episode include peri‑
odic worsening of renal function (which may fa‑
vor the accumulation of a drug, particularly dab‑
igatran), features of liver function impairment, 
low platelet count, etc. According to comparative 
trials (without head ‑to ‑head comparisons), up‑
per and lower gastrointestinal bleeding occurs 
more often among patients treated with dabiga‑
tran and rivaroxaban (mainly due to the presence 
of high amounts of an active drug in the gastro‑
intestinal tract) than in those treated with war‑
farin, while it occurs at a similar rate compared 
with patients treated with apixaban (which is also 
eliminated by the kidneys only in approximately 
25%, and is considered a safer option when creat‑
inine clearance is low, especially 30–40 ml/min). 
So if we are able to exclude the modifiable risk 
factor for bleeding (particularly the use of other 
drugs, mainly NSAIDs) and if the kidney function 
and platelet count are normal, we should reas‑
sess the bleeding risk. Then, we should either use 
a reduced dose of the same drug or switch anti‑
coagulants. Many experts recommend reducing 
the dose of NOAC among patients after serious 
bleeding and among most patients older than 75 
years; dabigatran 2 × 110 mg/d at such age is cur‑
rently recommended by the ESC. If bleeding re‑
curs (eg, gastrointestinal bleeding of unknown 
cause), a reinitiation of VKA therapy with regular 
INR monitoring and target INR values of 2 to 2.5 
should be considered. After an episode of serious 
bleeding, LMWH should be used for a short time, 
usually up to 4 weeks, especially when addition‑
al invasive diagnostic procedures are planned.
As a primary care physician, I frequently encounter 
patients asking to prescribe them LMWH instead of 
ASA before an elective procedure, such as dilation 
and curettage, colonoscopy with polypectomy, or cat‑
aract surgery. Are there any new recommendations 
for these particular patients? LMWH should not 
be used as bridging therapy in patients on long‑
‑term ASA treatment for the prevention of car‑
diovascular events. First of all, LMWH do not in‑
hibit platelet function. Secondly, most invasive 
procedures, including those with high bleeding 
risk (eg, cardiac surgeries), can be performed in 
patients taking ASA or other NSAIDs. ASA should 
not be discontinued before, for example, a cata‑
ract surgery in elderly patients after recent myo‑
cardial infarction (ie, with a strong indication to 
using ASA). Thirdly, LMWHs increase the risk of 
perioperative bleeding, and given at a prophylac‑
tic dose, they will surely not protect against myo‑
cardial infarction. Finally, if ASA is used for sec‑
ondary VTE prevention long after the primary 
incident, which is more and more common after 
